Linden Thomas Advisory Services LLC Purchases 473 Shares of DexCom, Inc. (NASDAQ:DXCM)

Linden Thomas Advisory Services LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 2.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 21,772 shares of the medical device company’s stock after purchasing an additional 473 shares during the period. Linden Thomas Advisory Services LLC’s holdings in DexCom were worth $1,693,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of DXCM. Public Sector Pension Investment Board lifted its holdings in shares of DexCom by 96.3% in the 2nd quarter. Public Sector Pension Investment Board now owns 16,842 shares of the medical device company’s stock valued at $1,910,000 after acquiring an additional 8,261 shares during the last quarter. APG Asset Management N.V. lifted its stake in shares of DexCom by 5.9% in the 2nd quarter. APG Asset Management N.V. now owns 309,500 shares of the medical device company’s stock valued at $32,742,000 after purchasing an additional 17,302 shares during the last quarter. MBB Public Markets I LLC purchased a new position in shares of DexCom in the 2nd quarter worth approximately $3,151,000. Maverick Capital Ltd. bought a new position in shares of DexCom during the 2nd quarter valued at approximately $1,889,000. Finally, The Manufacturers Life Insurance Company raised its holdings in DexCom by 0.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 289,824 shares of the medical device company’s stock valued at $32,860,000 after buying an additional 1,998 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Up 1.2 %

Shares of NASDAQ:DXCM opened at $88.75 on Friday. The company has a market capitalization of $34.67 billion, a PE ratio of 53.14, a P/E/G ratio of 2.23 and a beta of 1.12. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The business’s fifty day simple moving average is $79.50 and its 200-day simple moving average is $77.35. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on DXCM shares. Royal Bank of Canada cut their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company increased their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Canaccord Genuity Group boosted their target price on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Oppenheimer reduced their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, JPMorgan Chase & Co. boosted their price objective on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $99.29.

Insider Activity

In other news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.